Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 2531-2538

  Seetharam, Raviraja N ^a,b   Sood, Arjun ^a   Basu Mallick, Atrayee ^a   Augenlicht, Leonard H ^a,b   Mariadason, John M ^c   Goel, Sanjay ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Colorectal cancer; ERCC1; Gene silencing; Oxaliplatin; Resistance; siRNA

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; OXALIPLATIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; COLORECTAL CANCER; DRUG SENSITIVITY; EXCISION REPAIR; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HT29 CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION;

EID: 77955792964     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487, 2005.
2. Armand JP, Boige V, Raymond E, Fizazi K, Faivre S and Ducreux M: Oxaliplatin in colorectal cancer: an overview. Semin Oncol 27: 96-104, 2000.
3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
4. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F and de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27: 3109-3116, 2009.
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009
6. Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14: 1291-1295, 2008.
7. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F and Perego P: Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 3: 21-29, 2003. (Pubitemid 36119418)
8. Sancar A: DNA excision repair. Annu Rev Biochem 65: 43-81, 1996.
9. Petit C and Sancar A: Nucleotide excision repair: from E. coli to man. Biochimie 81: 15-25, 1999.
10. Altaha R, Liang X, Yu JJ and Reed E: Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14: 959-970, 2004.
11. Park CH, Bessho T, Matsunaga T and Sancar A: Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem 270: 22657-22660, 1995.
12. Biggerstaff M, Szymkowski DE and Wood RD: Co-correction of the ERCC1, ERCC4 and xeroderma pigmentosum group F DNA repair defects in vitro. EMBO J 12: 3685-3692, 1993.
13. Gillet LC and Scharer OD: Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev 106: 253-276, 2006. (Pubitemid 43316557)
14. Reardon JT and Sancar A: Nucleotide excision repair. Prog Nucleic Acid Res Mol Biol 79: 183-235, 2005.
15. Costa RM, Chiganças V, Galhardo Rda S, Carvalho H and Menck CF: The eukaryotic nucleotide excision repair pathway. Biochimie 85: 1083-1099, 2003. (Pubitemid 38142363)
16. Park CJ and Choi BS: The protein shuffle. Sequential interactions among components of the human nucleotide excision repair pathway. FEBS J 273: 1600-1608, 2006.
17. van Hoffen A, Balajee AS, van Zeeland AA and Mullenders LH: Nucleotide excision repair and its interplay with transcription. Toxicology 193: 79-90, 2003. (Pubitemid 37340145)
18. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anticancer chemotherapy. Cancer Treat Rev 24: 331-344, 1998.
19. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001. (Pubitemid 33096777)
20. Arnould S, Hennebelle I, Canal P, Bugat R and Guichard S: Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39: 112-119, 2003. (Pubitemid 36005433)
21. Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY and You HJ: Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 327: 225-233, 2005.
22. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S and Pendyala L: In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48: 398-406, 2001.
23. Arango D, Wilson AJ, Shi Q, Corner GA, Arañes MJ, Nicholas C, Lesser M, Mariadason JM and Augenlicht LH: Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91: 1931-1946, 2004.
24. Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, Aranes MJ, Lesser M, Schwartz EL and Augenlicht LH: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63: 8791-8812, 2003. (Pubitemid 38064059)
25. http://rsbweb.nih.gov/ij/download.html
26. http://www.sanger.ac.uk/genetics/CGP/cosmic/
27. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R and Mariadason JM: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953-1961, 2008.
28. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D and Viele C: The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12: 38-50, 2007. (Pubitemid 46143501)
29. Gossage L and Madhusudan S: Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33: 565-577, 2007. (Pubitemid 47355341)
30. Lenz HJ, Zhang W, Shi MM, Jacques C, Barrett JC, Danenberg KD, Hoffmann AC, Trarbach T, Folprecht G, Meinhardt G and Yang D: ERCC-1 gene expression levels and outcome to FOLFOX chemotherapy in patients enrolled in CONFIRM1 and CONRRM2. J Clin Oncol 26: 2008 (May 20 suppl; abstr 4131, 2008 ASCO Annual Meeting).
31. Iqbal S and Lenz HJ: Determinants of prognosis and response to therapy in colorectal cancer. Curr Oncol Rep 3: 102-108, 2001.
32. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T and Soria JC; IALT Bio Investigators: DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006. (Pubitemid 44343542)
33. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H and Katsaros D: ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 25: 5172-5179, 2007. (Pubitemid 350232247)
34. Jae Jin Lee S-YK, Sun Kyung Baek, Yoon Wha Kim, Hwi Joong Yoon and Kyung Sam Cho: ERCC expression is not a predictor for estimating outcomes of patients treated with cisplatin as an adjuvant therapy in curatively resected gastric cancer, Experimental and Molecular Therapeutics 12: Mechanisms of Resistance and Sensitivity to Platinum-based Compounds, Proc AACR, Vol 46, Abstract 1496, 2005.
35. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F and Reed E: Cisplatin induction of ERCC1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 273: 23419-23425, 1998. (Pubitemid 28417531)
36. Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung MH and You HJ: Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res 64: 4849-4857, 2004.
37. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
38. Hwang BJ, Ford JM, Hanawalt PC and Chu G: Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci USA 96: 424-428, 1999.
39. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F and Reed E: Association between the level of ERCC1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20: 645-652, 2000. (Pubitemid 30240614)